MannKind Receives FDA Approval for Furoscix ReadyFlow Autoinjector for Edema in Heart Failure and CKD
company_name:
MannKind Corporation
product_name:
Furoscix ReadyFlow™ (furosemide injection)
use_case:
treatment of edema (fluid overload) in adults with heart failure or chronic kidney disease
key_benefit:
delivers IV-equivalent diuretic effect in under 10 seconds, enabling at-home use and earlier intervention outside the hospital setting
status:
FDA approved as of July 24, 2026
commercial_availability:
expected in the United States by the end of August 2026
administration_time:
reduces administration time from about 5 hours with the existing on-body infusor to under 10 seconds
Sources:
MannKind Announces FDA Approval of Furoscix ReadyFlow ...
Mannkind Wins FDA Nod For Furoscix ReadyFlow, Announces $50 Mln Private Placement
FDA Accepts Furosemide Autoinjector sNDA for Treatment ...
How Investors May Respond To MannKind (MNKD) Winning FDA Approval For At‑Home Furoscix Autoinjector
MannKind Corporation's Post - LinkedIn
Self-administered furosemide injector approved
MannKind Shares FUROSCIX® Business Updates